As part of the agreement, DSM paid Crucell an undisclosed amount in exchange for additional license rights and a higher share of future licensing income.
Since December 2002, DSM Biologics and Crucell have been jointly outlicensing PER.C6 human cell line to third parties as a production platform for monoclonal antibodies and recombinant proteins. The parties recently established the PERCIVIA PER.C6 Development Center in the US as a joint venture to further develop the PER.C6 cell line.
The PER.C6 technology is a cell line developed for the large-scale manufacture of biopharmaceutical products including vaccines.
According to the companies, compared to conventional production technologies, the strengths of the PER.C6 technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. It also supports the growth of both human and animal viruses.